Mar 19, 2024 · RSV is a significant cause of acute respiratory infection, lower respiratory tract disease (LRTD), clinical complications, and death in infants and older adults. The U.S. Food and Drug Administration (FDA) approved the first vaccines against RSV in 2023.

Feb 15, 2023 · In this trial, one dose of the Ad26.RSV.preF–RSV preF protein vaccine was efficacious against RSV-mediated lower respiratory tract disease in adults 65 years of age or older.

Apr 5, 2023 · In this phase 3, double-blind trial conducted in 18 countries, we randomly assigned, in a 1:1 ratio, pregnant women at 24 through 36 weeks’ gestation to receive a single intramuscular injection of...

May 31, 2023 · ABRYSVO is a vaccine indicated for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in people 60 years of age and older. IMPORTANT SAFETY INFORMATION FOR ABRYSVO. Fainting can happen after getting injectable vaccines, including ABRYSVO.

Mar 23, 2023 · We have previously shown that a prefusion (preF) conformation-stabilized RSV F protein antigen and an adenoviral vector encoding RSV preF protein (Ad26.RSV.preF) are immunogenic and...

ABRYSVO is a vaccine indicated for active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age.

Mar 16, 2023 · Here we evaluate the breadth of the protective immune responses across RSV A and RSV B subtypes, induced by vaccines based on the RSV A-based fusion protein, stabilized in the prefusion conformation (preF) in preclinical models.

Aug 23, 2023 · RSVPreF3 is a recombinant F protein engineered to be stabilized in the preF conformation with the purpose of inducing or boosting RSV preF-specific antigenic sites (Ø and V)–binding antibody responses and thus RSV-neutralizing responses.

Background: Ad26.RSV.preF-RSV preF protein showed 80·0% vaccine efficacy against respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in older adults during one RSV season. No RSV vaccines have shown three-season efficacy.

In this study, Ad26.RSV.preF alone and Ad26.RSV.preF–RSV preF protein combinations elicited favorable ratios of RSV postF binding to RSV nAbs, which is promising for the potential of the vaccine to induce protective immunity in adults without priming for enhanced disease.